Boustead Singapore (F9D) on Jul, 24 2026 released a compilation of substantial shareholders’ questions and the Board’s responses ahead of its annual general meeting scheduled for Jul, 30 2026 at 2:30 p.m.
The company clarified that a year-end revision to accounting estimates for multi-year contracts in the Geospatial Division reduced fiscal-year 2026 revenue recognition but does not alter underlying cash flows or the recurring nature of the contracts. Management added that the change primarily affected the timing of revenue and lowered reported operating margin, while gross margin remained broadly intact. Prior-year divisional results were not overstated; restatements reflected presentation changes only.
On Real Estate Solutions, Boustead explained that it chose not to terminate a non-compete arrangement with a joint-venture partner, leading to a dilution of its stake in UIB Group from 19.7 % to 17.9 %, a move it said aligns with its strategy to retain operating control of Vietnam real-estate interests. The group also confirmed it will not finance a roughly 400 million Singapore dollars public-sector construction contract for which it is engaged purely as engineering and construction service provider.
For Healthcare, the firm highlighted its investment in UroMedTech, noting that the urology-focused robotics business complements Boustead Medical Care Holdings’ rehabilitation and digital healthcare strategy and offers recurring revenue potential.
Regarding profitability, Boustead cited higher competition, cost pressures and geopolitical factors—including supply-chain disruptions stemming from the US-Iran conflict—as reasons for margin compression in fiscal 2026. New engineering contracts booked in early fiscal 2027 largely reflect stable margins; of the 840 million Singapore dollars engineering order backlog, most revenue is expected within 12-18 months, with larger projects stretching up to three years.
Dividend policy remains unchanged: the Board will continue to weigh ordinary and potential special payouts against cash levels, outlook and strategic objectives, without committing to a fixed payout ratio.
Boustead’s Q&A document, together with its FY2026 annual and longevity reports, is available on SGXNET and the company’s website.